Nextcure announces initiation of phase 1b/2 clinical trial to evaluate nc410 in combination with keytruda® (pembrolizumab) in patients with immune checkpoint refractory or naÏve solid tumors

Beltsville, md., oct. 04, 2022 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a phase 1b/2 clinical trial to evaluate nc410 in combination with keytruda® (pembrolizumab), merck's anti-pd-1 therapy, in patients with immune checkpoint refractory or immune checkpoint naÏve solid tumors. in addition, nextcure announced it has entered into a supply agreement for keytruda with merck (known as msd outside the united states and canada).
NXTC Ratings Summary
NXTC Quant Ranking